CEDAR KNOLLS, N.J.,
Jan. 23, 2019 /PRNewswire/
-- MYOS RENS Technology Inc. ("MYOS" or "the Company")
(NASDAQ: MYOS), an advanced nutrition company and the owner of
Fortetropin®, a proprietary bioactive composition
derived from fertilized egg yolk that helps build lean muscle, has
issued the following letter to shareholders from CEO Joseph Mannello.
To our loyal shareholders:
On Sunday, January 20, very
exciting scientific results from a study that we sponsored with
Kansas State University were presented
at the North American Veterinary Community (NAVC) Conference/VMX in
Orlando, Florida. The
top-line results from this study were previously announced in a
press release issued on January 15. The principal
investigator of the study, Kenneth R.
Harkin, DVM, DACVIM (SAIM), Professor & Section Head,
Kansas State University College of Veterinary
Medicine gave a well-received presentation at the
conference, entitled, "The Impact of Fortetropin®
Supplementation on Dogs Recovering from Tibial-Plateau Leveling
Osteotomy (TPLO) Surgery," based on the study.
VMX is one of the largest conferences in the world dedicated to
Veterinary Medicine with over 17,000 delegates and over 700
exhibiting companies in attendance. I attended VMX and
spoke directly with veterinarians at the MYOS booth, where
there was tremendous activity and interest. Many of these
veterinarians said that they believe that our new
Fortetropin®-based product, MYOS Canine Muscle
Formula® will be a "game-changer" as there is
"finally" a product that is effective in the canine market for
muscle health. We believe that the study results will
have truly transformative potential for the Company. Below is
a brief discussion regarding the study and its potential impact on
our business.
The Kansas State University
Study
The study at Kansas State University
evaluated the impact of Fortetropin on attenuating muscle
loss in dogs during the weeks that follow a common veterinary
surgical procedure called TPLO surgery– a procedure that veterinary
surgeons perform to repair ruptures of the cranial cruciate
ligament (CCL) in dogs. The CCL has a function that is analogous to
the anterior cruciate ligament (ACL) in humans. Because the
affected limb is immobilized for several weeks after TPLO surgery,
a significant degree of muscle loss takes place during the eight
weeks that follow surgery. The adage "use it or lose it" very much
applies to muscle in all species– when muscle is not used, muscle
is lost due to disuse.
In our study, 50 dogs received Fortetropin, our proprietary
nutrition product, on a daily basis, while 50 dogs received cheese
powder as a macronutrient matched placebo. The key findings
of the study were as follows:
- Fortetropin minimized muscle loss in both the affected and
unaffected limbs of the dogs.
- Dogs that received Fortetropin had improved weight-bearing
capacity on their operated limb, and,
- Fortetropin prevented a rise in myostatin levels following
surgery. Myostatin is a protein that "puts the brakes" on
muscle growth and development.
The full study results will be submitted for publication in a
scientific journal in the coming months.
"Restoration or maintenance of muscle mass through the reduction
of myostatin levels with Fortetropin offers vets an approach to
in-home rehabilitation of injured dogs, including potentially
improving or restoring mobility in geriatric dogs," commented
Professor Harkin.
Transformation of MYOS
We believe these results will enable us to transform our
business in two ways. Relating to the near-term opportunity, MYOS
entered the veterinary market in 2018, when we developed and
launched MYOS Canine Muscle Formula®. The
decision to launch this product was based on very positive
testimonials from veterinarians and customers who reported positive
changes in their pets while using Fortetropin that were nothing
short of amazing. Many of these testimonials can be found at
www.myospet.com. As exciting as these testimonials were, it
became clear that scientific data from a well-designed,
placebo-controlled study would be needed to develop and grow our
business. We now have scientific data supporting these
testimonials which will form the backbone of our marketing efforts
to further commercialize MYOS Canine Muscle Formula.
The long-term potential associated with these study results
support our entry into the medical nutrition market. In 2016, MYOS
published results from a human clinical study at the University of Tampa which demonstrated that 18- to
21-year-old males who consumed Fortetropin on a daily basis while
performing moderate resistance training gained significantly more
muscle mass relative to the placebo group. Based on the
results observed in dogs at Kansas
State along with previous results observed in humans, we
strongly believe that Fortetropin has the potential to reduce
muscle atrophy in humans following injury and to enhance their
recovery. In light of these study results, we plan to
aggressively move forward with a human clinical study on the impact
of Fortetropin on recovery after total knee replacement
surgery. Positive results from this study would enable us
to participate in the recovery and rehabilitation field, a growing
market with tremendous potential.
It has been my goal to manage the Company in a financially
prudent manner in order to remain nimble and flexible so that we
can make strategic investments that will generate a very high
return on investment. With compelling results from a large
preclinical study in dogs regarding the impact of Fortetropin on
muscle atrophy, we feel confident to move forward with a human
clinical study related to muscle atrophy after total knee
replacement surgery.
To conclude, I am very optimistic about the future of the
Company. I believe that we have a tremendous foundation to
succeed in diverse areas ranging from sports nutrition to
rehabilitation and recovery to animal health. I look forward
to updating shareholders as we continue to leverage our R&D to
grow brands with outstanding value.
Joseph Mannello
Chief Executive Officer
About MYOS RENS Technology Inc.
MYOS RENS
Technology Inc. (MYOS), "The Muscle Company®", is a
Cedar Knolls, NJ-based
bionutrition company that develops and markets products that
improve muscle health and performance. MYOS is the owner of
Fortetropin®, a fertilized egg yolk-based product
manufactured via a proprietary process to retain and optimize its
biological activity. Fortetropin has been clinically shown to
increase muscle size and lean body mass in conjunction with
resistance training. MYOS believes Fortetropin has the potential to
redefine existing standards of physical health and wellness. For
more information, please visit www.MYOSRENS.com.
Forward-Looking Statements
Any statements in
this release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the successful launch of our products,
including Qurr®, Yolked®, MYOS
Enteral Nutrition Formula™ and MYOS Canine Muscle
Formula® products, the success of our research and
development, the results of the clinical evaluation of
Fortetropin® and its effects, including the study
results described herein, the ability to enter into new partnership
opportunities and the success of our existing partnerships, the
ability to generate the forecasted revenue stream and cash flow
from sales of our products, the ability to continue increasing our
revenue and gross profit margins, the ability to achieve a
sustainable, profitable business, the effect of economic
conditions, the ability to protect our intellectual property
rights, competition from other providers and products, the
continued listing of our securities on the Nasdaq Stock Market,
risks in product development, our ability to raise capital to fund
continuing operations, and other factors discussed from time to
time in our filings with the Securities and Exchange
Commission. We undertake no obligation to update or revise any
forward-looking statement for events or circumstances after the
date on which such statement is made except as required by
law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure or prevent any disease.
Investor Relations:
Porter LeVay & Rose
Michael Porter, President
Phone: 212-564-4700
Email: MYOS@plrinvest.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/myos-ceo-joseph-mannello-issues-letter-to-shareholders-following-presentation-at-north-american-veterinary-community-navc-conferencevmx-300782416.html
SOURCE MYOS RENS Technology